Can Marijuana Help With Opioid Withdrawal?

Early research suggests that certain compounds in marijuana, particularly CBD, can reduce opioid cravings and ease some withdrawal symptoms, but the evidence is still thin and the story is far more complicated than “smoke weed, feel better.” Most of the clinical data comes from small trials, and the handful of findings that do look promising involve pharmaceutical-grade cannabinoids rather than the joint you might pick up at a dispensary. Meanwhile, there are real risks that using cannabis during opioid recovery could introduce new problems, including drug interactions and a statistically elevated chance of developing opioid misuse in the first place.

Why Cannabinoids and Opioids Talk to Each Other at All

The endocannabinoid system and the opioid system are not strangers. They share overlapping real estate in the brain, and the receptors they activate sometimes sit on the same neurons. Research using advanced imaging in mice found that the cannabinoid CB1 receptor and the mu-opioid receptor are co-expressed on about half of certain neurons in the paraventricular nucleus of the thalamus, a region involved in stress and arousal. In pain-related areas like the periaqueductal gray and reward-related areas like the nucleus accumbens, the overlap was smaller but still present.¹ This cross-talk is the biological reason researchers have pursued cannabis-based interventions for opioid dependence in the first place. Animal and clinical studies both point to interactions between these two systems, suggesting that targeting the endocannabinoid system could offer new ways to manage opioid withdrawal and dependence.²

The practical upshot is that when you activate cannabinoid receptors, the opioid system can feel the ripple. That does not automatically mean the ripple is helpful, but it does mean there is a plausible biological basis for studying cannabis compounds in the context of opioid withdrawal rather than just hoping for an accidental benefit.

CBD Appears to Reduce Cravings and Anxiety

The strongest human evidence so far comes from CBD, the non-intoxicating compound in cannabis. A double-blind, placebo-controlled trial tested CBD in people who had been abstinent from heroin. When researchers showed them drug-related cues designed to trigger craving, those who received CBD reported significantly less craving and anxiety compared to the placebo group. CBD also reduced their heart rate and cortisol levels in response to those cues. Perhaps most interesting, the effect did not disappear immediately: participants still showed reduced craving a full week after their last CBD dose, even though the dosing period was only three days. No serious side effects were reported, and cognitive function was unaffected.³

A systematic review of CBD’s potential for treating opioid use disorder confirmed the pattern: human clinical studies consistently showed reduced craving and relief from the anxiety that accompanies abstinence.⁴ CBD also has a list of properties that read like a wish list for managing withdrawal. It has shown anti-anxiety, antidepressant, anti-inflammatory, anti-nausea, and pain-relieving effects, and it appears to be well tolerated even when given alongside potent opioid medications.⁵

Before anyone runs to a CBD store, though, a few caveats. The heroin craving trial used pharmaceutical-grade CBD at controlled doses. Over-the-counter CBD products vary wildly in purity and concentration, and the doses studied clinically are typically much higher than what most commercial products contain. Reducing craving is also not the same as treating withdrawal head-on. Craving is a relapse trigger, and blunting it matters enormously for long-term recovery, but it is a different beast from the sweating, vomiting, and muscle pain of acute withdrawal.

THC and Dronabinol for Acute Withdrawal

THC, the compound that gets you high, has a more complicated track record. Most of the clinical work uses dronabinol, a synthetic form of THC available by prescription. In one study of opioid-dependent participants going through withdrawal, dronabinol at lower doses (5 and 10 milligrams) looked essentially like a placebo. Higher doses of 20 and 30 milligrams showed modest signals of withdrawal suppression, but they also came with increased sedation, a feeling of being high, reports of feeling “bad effects,” racing heart sensations, and actual elevated heart rate.⁶ A dose that eases withdrawal while making you feel terrible and spiking your heart rate is not exactly a home run.

A separate trial told a slightly more encouraging story. When dronabinol was given during inpatient detoxification alongside the transition to extended-release naltrexone (a medication that blocks opioid effects), it significantly reduced the severity of withdrawal compared to placebo.⁷ The key word here is “adjunctive.” Dronabinol was added on top of standard medical detox, not used as a standalone treatment. This distinction matters because opioid withdrawal, while rarely fatal in otherwise healthy adults, can be medically serious and should not be managed with improvised remedies alone.

Animal studies add useful context. In rhesus monkeys experiencing morphine withdrawal, the highest dose of THC tested reduced some physical signs of withdrawal and lowered heart rate. But THC was not more effective than lofexidine, a non-opioid medication already approved for managing withdrawal symptoms. And when CBD was given alone or combined with THC, it had no significant effect on withdrawal signs in those monkeys.⁸ That last point is worth sitting with. In a controlled primate model, the CBD that looks so promising for craving and anxiety in humans did not move the needle on physical withdrawal symptoms. This suggests CBD and THC may each target different pieces of the withdrawal puzzle, and neither covers all of it.

The Gut and Pain Angle

Anyone who has experienced opioid withdrawal knows the gastrointestinal symptoms are among the worst parts: nausea, vomiting, diarrhea, and stomach cramping. CBD has gotten attention here precisely because its anti-nausea and anti-inflammatory properties could, in theory, address these symptoms without the intoxication of THC. In mouse studies, CBD reduced the severity of gastrointestinal withdrawal symptoms in a dose-dependent way, meaning higher doses worked better. The effect held in both male and female mice, although the results were somewhat stronger in males.⁹

This is genuinely interesting but still preclinical. No human trial has yet demonstrated that CBD reliably controls the gut symptoms of opioid withdrawal at tolerable doses. Mouse biology does not always translate to human biology, and the doses used in animal research are often scaled differently than what humans would take. Still, the animal data gives researchers a reason to keep pursuing this line of inquiry.

Does Using Cannabis Help People Stay in Treatment?

One of the most important outcomes in opioid recovery is whether someone stays on their medication-assisted treatment long enough for it to work. If cannabis helped with that, it would be a meaningful contribution even if the mechanism was just “it makes the early days more bearable.” The studies here are genuinely mixed.

One longitudinal analysis found that people who used cannabis daily had about 21% higher odds of staying on opioid agonist treatment compared to non-users, even after adjusting for other factors that might explain the difference.¹⁰ That sounds positive, but other studies tell a different story. A study looking specifically at methadone treatment found no significant relationship between frequent cannabis use and retention at six months.¹¹ And a study examining people on various forms of medication for opioid use disorder found that frequent cannabis users and infrequent or non-users had similar treatment retention rates, similar days abstinent from non-prescribed opioids, and similar rates of heavy drinking and other substance use.¹²

Reading these together, the honest summary is that cannabis use during opioid treatment does not appear to dramatically help or hurt retention. The one study showing a modest positive association is outnumbered by studies showing no meaningful difference. This is one of those areas where the evidence is thin enough that strong claims in either direction are premature.

People Are Already Substituting Cannabis for Opioids

Whether or not clinical trials fully endorse it, patients are already using cannabis as a substitute for opioid pain medications in large numbers, and they are vocal about their experience. In a survey of medical cannabis patients, among those who had used opioid-based pain medication, the vast majority reported being able to decrease their opioid intake when using cannabis alongside it. About seven in ten agreed that cannabis provided comparable pain relief, and over nine in ten said they preferred cannabis to opioids for their condition and would be more likely to choose it if it were easier to access.¹³ Other observational studies found roughly similar patterns, with about 80% of medical cannabis users reporting they substituted cannabis for traditional pain medications, citing fewer side effects and better symptom management.¹⁴

A cross-sectional survey of authorized medical cannabis patients found that prescription drugs were the most commonly substituted category, with opioid medications making up about a third of all specific drug substitutions. Among those who specifically switched away from opioids, nearly 60% reported stopping opioid use entirely.¹⁵

These numbers are striking, but they come with an important limitation: they are all self-reported by people who already chose to use medical cannabis. There is no randomized controlled trial confirming that cannabis works as well as opioids for pain, and people who select into cannabis use are not a representative sample. Someone for whom cannabis works well is more likely to keep using it and respond enthusiastically to a survey. Still, the sheer consistency of these reports across multiple studies and populations suggests something real is happening for at least a subset of chronic pain patients.

State Cannabis Laws and Overdose Deaths

If cannabis were genuinely helping large numbers of people reduce opioid use, you might expect to see it reflected at the population level: fewer overdose deaths in states that legalized medical cannabis. Early research seemed to confirm exactly that. A widely cited analysis found that states with medical cannabis laws had about 25% lower annual opioid overdose mortality rates, and the association appeared to get stronger over time.¹⁶

This finding was a bombshell in both the research and policy worlds. But the story did not end there. When researchers extended the analysis beyond 2010 with more years of data, the association did not just weaken. It flipped. The original reduction disappeared, and a positive association of about 23% emerged, meaning states with medical cannabis laws actually showed higher opioid overdose mortality in the extended time frame. Neither recreational cannabis laws nor low-THC cannabis laws showed any association with changes in overdose mortality. The researchers concluded that since only about 2.5% of the U.S. population uses medical cannabis, it is unlikely to have exerted the large conflicting effects the data seemed to show. A more plausible explanation is that the original finding was spurious, driven by other policy changes and economic shifts happening in those same states during that period.¹⁷

A separate pooled analysis similarly found that medical marijuana legalization was associated with a statistically insignificant 8% reduction in opioid overdose mortality, though it did find a small but significant 7% reduction in the volume of prescription opioids dispensed.¹⁸ If you still hear the claim that “states with legal weed have fewer overdose deaths,” that is based on an analysis that has been effectively overturned by longer-term follow-up.

Cannabis Use May Increase Opioid Risk in Some Populations

This is the part of the story that proponents of cannabis-for-opioid-withdrawal tend to skip. A large epidemiological study found that cannabis users were roughly two and a half times as likely to begin nonmedical use of prescription opioids and about twice as likely to develop opioid use disorder after adjusting for background characteristics like demographics and other substance use.¹⁹ A systematic review and meta-analysis looking at the transition from cannabis use to opioid use and opioid use disorders found similar numbers: cannabis users had nearly three times the odds of transitioning to opioid use and about two and a half times the odds of developing an opioid use disorder compared to non-users.²⁰

These associations do not prove that cannabis causes opioid misuse. People who use any substance are more likely to use other substances for a range of overlapping reasons, including genetics, environment, mental health, and social context. But they do mean that recommending cannabis broadly as an opioid withdrawal tool carries a different risk profile than recommending, say, a non-addictive blood pressure medication repurposed for withdrawal symptoms. Clinicians weighing the potential benefit of cannabinoids for a patient in withdrawal have to consider whether cannabis use could create its own set of problems down the line.

A Drug Interaction Worth Knowing About

People going through opioid withdrawal are often already on medications like buprenorphine (sold under brand names like Suboxone and Subutex), and cannabis can change how those medications behave in the body. A study comparing buprenorphine patients who used cannabis to those who did not found that cannabis users had nearly three times higher blood concentrations of buprenorphine, despite receiving the same dose. The reason appears to be that cannabis inhibits the liver enzyme responsible for breaking down buprenorphine, essentially slowing its metabolism and causing it to build up in the bloodstream.²¹

Higher buprenorphine levels could mean more side effects, including increased sedation and respiratory depression, especially in someone not accustomed to that medication level. It could also complicate dosing adjustments if a clinician does not know about the cannabis use. If you are on buprenorphine and considering using cannabis for any reason, your prescriber needs to know so that dosing can be monitored appropriately.

Endocannabinoid System Drugs Beyond Whole-Plant Cannabis

Some of the most intriguing research does not involve cannabis itself but rather drugs that manipulate the body’s own endocannabinoid system. The idea is to boost the natural cannabinoids your body already produces rather than flooding receptors with external THC or CBD. In mice going through morphine withdrawal, drugs that block the enzymes that break down endocannabinoids significantly reduced jumping behavior, a classic physical sign of withdrawal in rodents. THC also reduced jumping, but through a different route. Interestingly, one of the endocannabinoid-boosting drugs reduced jumping without producing the place aversion that withdrawal normally causes, which could mean it eased some symptoms without fully blocking the negative experience.²²

These compounds are nowhere near human clinical use. But they represent a possible future in which the cannabinoid system is targeted with precision rather than by smoking or eating a plant that contains hundreds of compounds at once. If a specific enzyme inhibitor can reduce withdrawal severity without producing a high or creating dependency, that would sidestep many of the concerns around using whole-plant cannabis.

What None of This Replaces

The standard treatments for opioid withdrawal and opioid use disorder remain methadone, buprenorphine, and naltrexone. These are supported by decades of large-scale research showing they reduce overdose deaths, improve treatment retention, and decrease illicit opioid use. Cannabis-based approaches, even in the most optimistic reading of the current evidence, are being studied as add-ons to these treatments, not replacements. The dronabinol trial that showed reduced withdrawal severity, for instance, was specifically designed to help patients tolerate the transition to naltrexone, not to substitute for it.

People experiencing opioid withdrawal sometimes reach for cannabis because it is accessible, legal in many states, and feels safer than going back to opioids. That instinct is understandable, and the evidence does not suggest cannabis use during treatment is catastrophic. But the most favorable data applies to isolated cannabinoids at controlled doses under clinical supervision, which is a very different thing from self-medicating with whatever happens to be available. If you or someone you know is going through opioid withdrawal, the first call should be to a clinician who can prescribe evidence-based medications. Cannabinoid research may eventually expand the toolkit, but right now it is more promising than proven.